You are here: Industry Insights > Luxturna

News List

Amid Zolgensma crisis, Novartis gets a gene therapy boost as NICE embraces Luxturna biospectrumasia
September 08, 2019
In December 2017, Luxturna became the first directly administered gene therapy approved in the U.S. Now, it’s recommended for use on the NHS in England.
Cell therapy produces encouraging first results in eye trial pharmaphorum
February 26, 2019
UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).
Novartis plots 'innovative' payment models for pricey Luxturna's EU launch fiercepharma
November 27, 2018
It’s been almost a year since Spark Therapeutics won a groundbreaking gene therapy approval in the U.S. for Luxturna, and now its marketing partner Novartis has done the same across the pond.
Novartis/Spark’s sight gene therapy approved in EU pharmaphorum
November 27, 2018
Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.
EU OKs Novartis’ gene therapy Luxturna for rare retinal disease pharmatimes
November 26, 2018
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Novartis' gene therapy Luxturna becomes first approved European therapy for vision loss subtype pharmafile
November 26, 2018
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to be marketed...
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines. pharmatimes
September 27, 2018
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region...
FDA approves Spark Therapeutics’ Luxturna for retinal dystrophy pharmaceutical-technology
December 22, 2017
Spark Therapeutics has gained US Food and Drug Administration (FDA) approval for its one-time gene therapy product, Luxturna (voretigene neparvovec-rzyl), to treat children and adults with biallelic RPE65 mutation-associated retinal dystrophy.
Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. biospace
December 20, 2017
FDA broke new ground today with a first-of-its-kind therapy for eye disease. The regulatory agency approved Spark Therapeutics' Luxturna (voretigene neparvovec), a gene therapy for a rare, genetic form of blindness.